Savara (SVRA) Introduces aPAP ClearPath
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St set for higher open on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Bernstein raises server shipment forecast as AI infrastructure spending grows
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
December 21, 2023 8:05 AM ESTThe simple, no-cost, and noninvasive test is now available to physicians in the U.S. Company launches campaign in the U.S. to raise awareness of the rare autoimmune lung disease and need for early testing
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq:... More
